Drug development and industrial pharmacy
Cure8 research brief
Why This Matters
A colon-targeted 5-ASA pellet could improve delivery of mesalamine to the diseased colon while reducing release in the stomach; that might increase effectiveness or reduce systemic exposure compared with standard formulations, if later validated in humans.
Who Should Pay Attention
Adults with ulcerative colitis, clinicians treating UC, and researchers working on drug-delivery or IBD therapeutics.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This pubmed-listed abstract reports a preclinical formulation study testing pH-sensitive pellets that encapsulate 5-ASA (mesalamine) in glyceryl monooleate/linoleic-acid liquid crystal nanoparticles for colon-targeted release in ulcerative colitis.
The authors describe in vitro release testing at acidic and near-neutral pH and an in vivo rat UC model comparing colon damage scores across groups.
The abstract states the pH-sensitive pellets released substantially more drug at pH 6.8 than at pH 1.2 and that the pH-triggered formulation produced a statistically significant reduction in colon damage scores in the animal model. Methods mentioned include extrusion–spheronisation to make pellets and characterization by microscopy, FTIR, and DSC.
This is a formulation and preclinical efficacy study (rat model) rather than a human clinical trial or regulatory report. It suggests a promising targeted-delivery approach for 5-ASA but does not provide clinical safety or efficacy data in people.
Keep In Mind
This report is based on an abstract describing in vitro work and an in vivo rat model; animal results don’t prove human benefit. The study focuses on drug formulation and preclinical efficacy measures rather than clinical outcomes or safety in people.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationDrug development and industrial pharmacy
AuthorsAli Asghar Khakshur, Abbas Akhgari, Hosseinzadeh Zahra +3 more
InstitutionStudent Research Committee, Mashhad University of Medical Sciences, Mashhad, Iran.
Study typeJournal article
Indexed viaPubMed
Source typeResearch paper
PublishedAug 12, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Application of thermo-responsive polymers as an enema formulation for the treatment of ulcerative colitis.
A rectal 5-ASA gel that forms in place and sticks to the mucosa could reduce leakage and improve drug retention, potentially increasing effectiveness and patient comfort for people using topical therapies for ulcerative...
Human factors validation study of a disposable autoinjector (Bmab 1200 autoinjector) for subcutaneous delivery of Ustekinumab.
Autoinjectors can make long-term biologic treatment easier, more convenient, and potentially improve adherence for people with Crohn’s disease or ulcerative colitis who use ustekinumab.
Corticosteroid therapy following infliximab rescue in acute severe ulcerative colitis: should they be continued?
For people with ulcerative colitis treated with infliximab for acute severe disease, whether to keep giving systemic corticosteroids afterward affects infection risk, steroid side effects, and disease control.